Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.25, $1.12 better than the analyst estimate of $4.13. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.49 billion.

GUIDANCE:

Biogen sees FY2022 EPS of $15.25-$16.75, versus the consensus of $15.54. Biogen sees FY2022 revenue of $9.9-10.1 billion, versus the consensus of $9.84 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• RBC bullish on Kraft Heinz, sees return to growth in 2027
• ON Semiconductor (ON) PT Lowered to $90 at Cantor Fitzgerald After Analyst Day
• The Bancorp (TBBK) PT Lowered to $75 at Piper Sandler